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Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
drop-down field to apply the provided criteria. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 34 prioritisation (January 2018), 15 drugs were filtered out of 405 identified and were sent 
to prioritisation. Of these, seven drugs were ranked as ‘highly relevant’ by the expert panel, seven 
as ‘relevant’ and one as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
No Filtered Drugs – 34th prioritisation 1st quarter 2018 
Overall 
category 
1. Lomustine and bevacizumab (Avastin
®
) in progressive glioblastoma Not relevant 
2. 
Nintedanib (Vargatef
®
) plus pemetrexed/cisplatin in patients with malignant pleural 
mesothelioma 
Relevant 
3. 
Nivolumab (Opdivo
®
) in patients with advanced gastric or gastro-oesophageal junction 
cancer refractory to, or intolerant of, at least two previous chemotherapy regimens 
Relevant 
4. Bosutinib (Bosulif
®
) versus imatinib for newly diagnosed chronic myeloid leukemia Relevant 
5. 
Incorporation of brentuximab vedotin (Adcetris
®
) into first-line treatment of advanced 
classical Hodgkin’s lymphoma 
Relevant 
6. 
Brentuximab vedotin (Adcetris
®
) with chemotherapy for stage III or IV Hodgkin’s 
lymphoma 
Relevant 
7. 
Rituximab (MabThera
®
) after autologous stem-cell transplantation in mantle-Cell 
lymphoma 
Highly 
relevant 
8. 
Daratumumab (Darzalex
®
) plus bortezomib, melphalan, and prednisone for untreated 
myeloma 
Highly 
relevant 
9. Abemaciclib (Verzenio
TM
) as initial therapy for advanced breast cancer 
Highly 
relevant 
10. 
Dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib 
(Tyverb
®
) plus trastuzumab in combination with an aromatase inhibitor in 
postmenopausal women with HER2-positive, hormone receptor–positive metastatic 
breast cancer 
Highly 
relevant 
11. 
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-
positive non-small-cell lung cancer 
Highly 
relevant 
12. 
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for 
patients with advanced EGFR mutation-positive lung adenocarcinoma 
Relevant 
13. 
Osimertinib (Tagrisso
®
) in untreated EGFR-mutated advanced non–small-cell lung 
cancer 
Highly 
relevant 
14. 
Ramucirumab (Cyramza
®
) plus docetaxel versus placebo plus docetaxel in patients with 
locally advanced or metastatic urothelial carcinoma after platinum-based therapy 
Relevant 
15. 
Rucaparib (Rubraca
®
) maintenance treatment for recurrent ovarian carcinoma after 
response to platinum therapy 
Highly 
relevant 
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1 Lymphoma 
1.1 Rituximab (MabThera®) after autologous stem-cell 
transplantation in mantle-cell lymphoma 
 
Overview 
Drug Description a monoclonal antibody targeting CD20 
Patient Indication 
rituximab as maintenance therapy in patients with mantle-cell lymphoma who 
had undergone autologous stem-cell transplantation 
Incidence in 
Austria 
936 newly diagnosed per year (2014), 11.3/100,000/year (European Standard 
Population, 2013) 
Ongoing Phase III - 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
07/2009: in combination with CHOP chemotherapy in non-Hodgkin' s 
Lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and as 
first-line in chronic lymphocytic leukaemia 
07/2011: in combination with chemotherapy for the treatment of patients with 
previously untreated and relapsed/refractory chronic lymphocytic leukaemia  
03/2013: in combination with glucocorticoids for the induction of remission in 
patients with severe, active granulomatosis with polyangiitis (Wegener’s) 
(GPA) and microscopic polyangiitis (MPA) 
FDA 
02/2006: for first-line treatment of patients with diffuse large B-cell, CD20-
positive, non-Hodgkin’s lymphoma in combination with cyclophosphamide, 
doxorubicin, vincristine and prednisone (CHOP) or other anthracycline-based 
chemotherapy regimens 
09/2006: for first-line treatment of patients with low grade or follicular B-cell, 
CD20-positive non-Hodgkin’s lymphoma 
02/2010: in combination with fludarabine and cyclophosphamide (FC), for the 
treatment of both previously untreated and previously treated patients with 
chronic lymphocytic leukaemia (CLL) 
01/2011: for maintenance therapy for patients with previously untreated 
follicular CD-20 positive B-cell non-Hodgkin lymphoma (NHL) who achieve a 
response to rituximab in combination with chemotherapy 
10/2012: for second-line treatment in patients with NHL who did not 
experience a grade 3 or 4 infusion-related adverse reaction during cycle 1 
Costs 
Rituximab: 
Maintenance therapy: IV 375 mg/m² body surface area (BSA) every 2 months 
for 3 years (assuming an average BSA of 1,73 m²); 
ex-factory price of 375 mg = € 1,150.22  € 1,989.88 per treatment 
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Phase III results  
NEJM; available online 28 September 2017 (Le Gouill et al.): “Rituximab after autologous stem-cell 
transplantation in mantle-cell lymphoma” 
Background 
Mantle-cell lymphoma is generally incurable. Despite high rates of complete response after initial 
immune chemotherapy followed by autologous stem-cell transplantation, patients have relapses. We 
investigated whether rituximab maintenance therapy at a dose of 375 mg per square meter of body-
surface area administered every 2 months for 3 years after transplantation would prolong the duration 
of response. 
 
Methods 
In a phase 3 trial involving 299 patients who were younger than 66 years of age at diagnosis, we 
randomly assigned 240 patients to receive rituximab maintenance therapy or to undergo observation 
after autologous stem-cell transplantation (120 patients per group); 59 patients did not undergo 
randomization. The primary endpoint was event-free survival (with an event defined as disease 
progression, relapse, death, allergy to rituximab, or severe infection) after transplantation among 
patients who underwent randomization. 
 
Results 
After four courses of immune chemotherapy induction (rituximab, dexamethasone, cytarabine, and a 
platinum derivative [R-DHAP]), the overall response rate was 89%, and the complete response rate 
77%. Transplantation was performed in 257 patients. The median follow-up from randomization after 
transplantation was 50.2 months (range, 46.4 to 54.2). Starting from randomization, the rate of event-
free survival at 4 years was 79% (95% confidence interval [CI], 70 to 86) in the rituximab group versus 
61% (95% CI, 51 to 70) in the observation group (p = 0.001). The rate of progression-free survival at 4 
years was 83% (95% CI, 73 to 88) in the rituximab group versus 64% (95% CI, 55 to 73) in the 
observation group (p<0.001). The rate of overall survival was 89% (95% CI, 81 to 94) in the rituximab 
group versus 80% (95% CI, 72 to 88) in the observation group (p = 0.04). According to a Cox 
regression unadjusted analysis, the rate of overall survival at 4 years was higher in the rituximab group 
than in the observation group (hazard ratio for death, 0.50; 95% CI, 0.26 to 0.99; p = 0.04). 
 
Conclusions 
Rituximab maintenance therapy after transplantation prolonged event-free survival, progression-free 
survival, and overall survival among patients with mantle-cell lymphoma who were younger than 66 
years of age at diagnosis. (Funded by Roche and Amgen; LyMa ClinicalTrials.gov number, 
NCT00921414.)  
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2 Multiple Myeloma 
2.1 Daratumumab (Darzalex®) plus bortezomib, melphalan, and 
prednisone for untreated myeloma 
 
Overview 
Drug Description 
human CD38-directed monoclonal antibody (CD38 is a transmembrane 
glycoprotein (48 kDa) expressed on the surface of hematopoietic cells) 
Patient Indication 
daratumumab plus bortezomib, melphalan, and prednisone for newly 
diagnosed multiple myeloma patients who were ineligible for autologous 
stem-cell transplantation 
Incidence in 
Austria 
382 newly diagnosed per year (2014), 4.3/100,000/year (European Standard 
Population, 2013) 
Ongoing Phase II - 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
05/2016: as a monotherapy for the treatment of adult patients with relapsed 
and refractory multiple myeloma, whose prior therapy included a proteasome 
inhibitor and an immunomodulatory agent and who have demonstrated 
disease progression on the last therapy 
 
02/2017: in combination with lenalidomide and dexamethasone, or 
bortezomib and dexamethasone, for the treatment of adult patients with 
multiple myeloma who have received at least one prior therapy 
FDA 
11/2015: as a single agent for the treatment of patients with multiple myeloma 
who have received at least three prior lines of therapy, including a 
proteasome inhibitor (PI) and an immunomodulatory agent, or who are 
double-refractory to a PI and an immunomodulatory agent 
 
11/2016: in combination with lenalidomide and dexamethasone, or 
bortezomib and dexamethasone, for the treatment of patients with multiple 
myeloma who have received at least one prior therapy 
 
06/2017: in combination with pomalidomide and dexamethasone for the 
treatment of patients with multiple myeloma who have received at least two 
prior therapies including lenalidomide and a proteasome inhibitor 
Costs 
Daratumumab: 
IV 16 mg/kg/once per week in cycle 1;400 mg  € 2,209.45; assuming an 
average body weight of 70 kg, 1,120 mg/week are needed and 3,360 mg/3 
weeks are needed; costs of €18,559.38 would incur for treatment cycle 1 (in 
cycles 2-9 daratumumab is administered every 3 weeks) 
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Phase III results  
NEJM; available online December 12, 2017 (Mateos et al.): “Daratumumab plus bortezomib, 
melphalan, and prednisone for untreated myeloma” 
Background 
The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with 
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. 
Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with 
relapsed or refractory multiple myeloma. 
 
Methods 
In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who 
were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and 
prednisone either alone (control group) or with daratumumab (daratumumab group) until disease 
progression. The primary endpoint was progression-free survival. 
 
Results 
At a median follow-up of 16.5 months in a pre-specified interim analysis, the 18-month progression-
free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group 
and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 
0.50; 95% CI, 0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab 
group, as compared with 73.9% in the control group (P<0.001), and the rate of complete response or 
better (including stringent complete response) was 42.6%, versus 24.4% (P<0.001). In the 
daratumumab group, 22.3% of the patients were negative for minimal residual disease (at a threshold 
of 1 tumour cell per 105 white cells), as compared with 6.2% of those in the control group (P<0.001). 
The most common adverse events of grade 3 or 4 were hematologic: neutropenia (in 39.9% of the 
patients in the daratumumab group and in 38.7% of those in the control group), thrombocytopenia (in 
34.4% and 37.6%, respectively), and anaemia (in 15.9% and 19.8%, respectively). The rate of grade 3 
or 4 infections was 23.1% in the daratumumab group and 14.7% in the control group; the rate of 
treatment discontinuation due to infections was 0.9% and 1.4%, respectively. Daratumumab 
associated infusion-related reactions occurred in 27.7% of the patients. 
 
Conclusion 
Among patients with newly diagnosed multiple myeloma who were ineligible for stem cell 
transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a 
lower risk of disease progression or death than the same regimen without daratumumab. The 
daratumumab-containing regimen was associated with more grade 3 or 4 infections. (Funded by 
Janssen Research and Development; ALCYONE ClinicalTrials.gov number, NCT02195479.) 
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3 Breast cancer 
3.1 Abemaciclib (VerzenioTM) as initial therapy for advanced breast 
cancer 
 
Overview 
Drug Description inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) 
Patient Indication 
abemaciclib as initial therapy for advanced HR-positive, HER2-negative 
breast cancer 
Incidence in 
Austria 
5,454 newly diagnosed per year (2014), 64.3 /100,000/year (European 
Standard Population, 2013) 
Ongoing Phase II NCT02246621 until 07/2021 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA - 
FDA 
09/2017: in combination with fulvestrant for women with HR-positive, HER2-
negative advanced or metastatic breast cancer with disease progression 
following endocrine therapy 
09/2017: as monotherapy for women and men with HR-positive, HER2-
negative advanced or metastatic breast cancer with disease progression 
following endocrine therapy and prior chemotherapy in the metastatic setting 
Costs - 
Phase III results  
JCO; available online October 2017: 35:32, 3638-3646 (Goetz et al.): “MONARCH 3: Abemaciclib 
as initial therapy for advanced breast cancer” 
Purpose 
Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and 
in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal 
growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine 
therapy. 
 
Methods 
MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a 
nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative 
advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received 
abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 
mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. 
Secondary objectives included response evaluation and safety. A planned interim analysis occurred 
after 189 events. 
 
Results 
Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 
0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in 
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the placebo arm). In patients with measurable disease, the objective response rate was 59% in the 
abemaciclib arm and 44% in the placebo arm (P = .004). In the abemaciclib arm, diarrhoea was the 
most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and 
placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhoea 
(9.5% v 1.2%), and leukopenia (7.6% v 0.6%). 
 
Conclusion 
Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly 
improving progression-free survival and objective response rate and demonstrating a tolerable safety 
profile in women with HR-positive, HER2-negative advanced breast cancer. 
 
3.2 Dual human epidermal growth factor receptor 2 (HER2) 
blockade with lapatinib (Tyverb®) plus trastuzumab in 
combination with an aromatase inhibitor in postmenopausal 
women with HER2-positive, hormone receptor–positive 
metastatic breast cancer  
 
Overview 
Drug Description 
small molecule dual inhibitor of HER1 (ErbB1) and HER2 (ErbB2) receptor 
tyrosine kinases 
Patient Indication 
lapatinib in postmenopausal women with HER2-positive/HR-positive 
metastatic breast (MBC) cancer who received prior endocrine therapy (ET) 
and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy 
Incidence in 
Austria 
5,454 newly diagnosed per year (2014), 64.3/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III - 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
06/2008: in combination with capecitabine for the treatment of patients with 
advanced or MCB whose tumours overexpress ErbB2 (HER2) 
06/2011: in combination with an aromatase in women who have been through 
the menopause, when the cancer is metastatic and responds to hormones 
06/2013: in combination with trastuzumab for the treatment of patients with 
hormone receptor (HR)-negative metastatic disease that has progressed on 
prior trastuzumab therapy(ies) in combination with chemotherapy 
FDA 
03/2007: in combination with capecitabine for the treatment of patients with 
advanced or MCB whose tumours overexpress HER2 and who have received 
prior therapy including an anthracycline, taxane, and trastuzumab 
01/2010: in combination with letrozole for the treatment of postmenopausal 
women with HR-positive MBC that overexpresses the HER2 receptor and for 
whom hormonal therapy is indicated 
Costs 
Lapatinib: 
1 treatment cycle (21 days): oral 1,000 mg/day or 1,500 mg/day; 
ex-factory price of 1,000 mg = € 70.58  € 1,482.18 per treatment cycle 
OR ex-factory price of 1,500 mg = € 105.86  € 2,223.06 per treatment 
cycle; 
Additional costs will occur due to the combination treatment of lapatinib with 
trastuzumab and an aromatase inhibitor (letrozole, anastrozole or 
exemestane). 
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Phase III results  
JCO: available online 15 December 2017 (Johnston et al.): “Phase III, randomized study of dual 
human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in 
combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone 
receptor–positive metastatic breast cancer: ALTERNATIVE” 
Purpose 
Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved 
clinical benefit in HER2-positive, hormone receptor (HR)–positive metastatic breast cancer (MBC) 
versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The 
ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase 
inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET 
and prior neo (adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy. 
 
Methods 
Patients were randomly assigned (1:1:1) to receive lapatinib (LAP) + TRAS + AI, TRAS + AI, or LAP + 
AI. Patients for whom chemotherapy was intended were excluded. The primary endpoint was 
progression-free survival (PFS; investigator assessed) with LAP + TRAS + AI versus TRAS + AI. 
Secondary endpoints were PFS (comparison of other arms), overall survival, overall response rate, 
clinical benefit rate, and safety. 
 
Findings 
Three hundred fifty-five patients were included in this analysis: LAP + TRAS + AI (n = 120), TRAS + AI 
(n = 117), and LAP + AI (n = 118). Baseline characteristics were balanced. The study met its primary 
endpoint; superior PFS was observed with LAP + TRAS + AI versus TRAS + AI (median PFS, 11 v 5.7 
months; hazard ratio, 0.62; 95% CI, 0.45 to 0.88; P = .0064). Consistent PFS benefit was observed in 
predefined subgroups. Overall response rate, clinical benefit rate, and overall survival also favoured 
LAP + TRAS + AI. The median PFS with LAP + AI versus TRAS + AI was 8.3 versus 5.7 months 
(hazard ratio, 0.71; 95% CI, 0.51 to 0.98; P = .0361). Common adverse events (AEs ≥ 15%) with LAP 
+ TRAS + AI, TRAS + AI, and LAP + AI were diarrhoea (69%, 9%, and 51%, respectively), rash (36%, 
2%, and 28%, respectively), nausea (22%, 9%, and 22%, respectively), and paronychia (30%, 0%, 
and 15%, respectively), mostly grade 1 or 2. serious AEs were reported similarly across the three 
groups, and AEs leading to discontinuation were lower with LAP + TRAS + AI. 
 
Conclusion 
Dual HER2 blockade with LAP + TRAS + AI showed superior PFS benefit versus TRAS + AI in 
patients with HER2-positive/HR-positive MBC. This combination offers an effective and safe 
chemotherapy-sparing alternative treatment regimen for this patient population. 
 
 
Horizon Scanning in Oncology    
 
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXXIV – HSS Onkologie Seite 11 von 15 
4 Lung cancer 
4.1 Dacomitinib versus gefitinib as first-line treatment for patients 
with EGFR-mutation-positive non-small-cell lung cancer 
 
Overview 
Drug Description second-generation, irreversible EGFR tyrosine kinase inhibitor 
Patient Indication 
dacomitinib for the first-line treatment of patients with advanced EGFR-
mutation-positive non-small-cell lung cancer  
Incidence in 
Austria 
4,716 newly diagnosed per year (2014), 56.9/100,000/year (European 
Standard Population, 2013) (including: lung, trachea and bronchial tumours) 
Ongoing Phase II - 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
Phase III results  
Lancet; available online September 2017: 18:11, 1454-1466 (Wu et al.): “Dacomitinib versus 
gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer 
(ARCHER 1050): a randomised, open-label, phase 3 trial” 
Background 
Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its 
efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line 
treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC). 
 
Methods 
In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled 
adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced 
NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and 
university hospitals in seven countries or special administrative regions. We randomly assigned 
participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day 
(in 28-day cycles) until disease progression or another discontinuation criterion was met. 
Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated 
random code assigned by a central interactive web response system. The primary endpoint was 
progression-free survival assessed by masked independent review in the intention-to-treat population. 
Safety was assessed in all patients who received at least one dose of study treatment. This study is 
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registered with ClinicalTrials.gov, number NCT01774721, and is ongoing but no longer recruiting 
patients. 
 
Findings 
Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive 
dacomitinib (n=227) or gefitinib (n=225). Median duration of follow-up for progression-free survival was 
22.1 months (95% CI 20.3–23.9). Median progression-free survival according to masked independent 
review was 14.7 months (95% CI 11.1–16.6) in the dacomitinib group and 9.2 months (9.1–11.0) in the 
gefitinib group (hazard ratio 0.59, 95% CI 0.47–0.74; p<0.0001). The most common grade 3–4 
adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs none of 224 
patients given gefitinib), diarrhoea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels 
(two [1%] vs 19 [8%]). Treatment-related serious adverse events were reported in 21 (9%) patients 
given dacomitinib and in ten (4%) patients given gefitinib. Two treatment-related deaths occurred in 
the dacomitinib group (one related to untreated diarrhoea and one to untreated cholelithases/liver 
disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by 
pneumonia). 
 
Interpretation 
Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of 
patients with EGFR-mutation-positive NSCLC and should be considered as a new treatment option for 
this population. 
 
4.2 Osimertinib (Tagrisso®) in untreated EGFR-mutated advanced 
non–small-cell lung cancer 
 
Overview 
Drug Description 
irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) that selectively inhibits both EGFR-TKI-sensitising and EGFR T790M 
resistance mutations 
Patient Indication 
osimertinib in patients with previously untreated, epidermal growth factor 
receptor (EGFR) mutation–positive advanced non–small-cell lung cancer 
(NSCLC) 
Incidence in 
Austria 
4,716 newly diagnosed per year (2014), 56.9/100,000/year (European 
Standard Population, 2013) (including: lung, trachea and bronchial tumours) 
Ongoing Phase III NCT02296125 until 06/2019 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
02/2016: for the treatment in patients with NSCLC, that is advanced or has 
spread and who have EGFR T790M mutation 
FDA 
03/2017: for the treatment of patients with metastatic EGFR T790M mutation-
positive NSCLC, who have progressed on or after EGFR tyrosine kinase 
inhibitor (TKI) therapy 
Costs 
Osimertinib: 
Dose: 80 mg/day; ex-factory price of 80 mg/30 days  € 6,132.50 of 30 days 
of treatment 
 
 
 
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXXIV – HSS Onkologie Seite 13 von 15 
Phase III results  
NEJM; available online 18 November 2017 (Soria et al.): “Osimertinib in untreated EGFR-mutated 
advanced non–small-cell lung cancer” 
Background 
Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase 
inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance 
mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, 
EGFR mutation–positive advanced non–small-cell lung cancer (NSCLC). 
 
Methods 
In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR 
mutation–positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either 
osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg 
once daily or erlotinib at a dose of 150 mg once daily). The primary endpoint was investigator-
assessed progression-free survival. 
 
Results 
The median progression-free survival was significantly longer with osimertinib than with standard 
EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% 
confidence interval [CI], 0.37 to 0.57; p<0.001). The objective response rate was similar in the two 
groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 
1.90; p = 0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with 
osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival 
were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% 
CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for 
death, 0.63; 95% CI, 0.45 to 0.88; p = 0.007 [non-significant in the interim analysis]). Adverse events 
of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% versus 
45%). 
 
Conclusions 
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR 
mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse 
events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125.)  
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5 Ovarian carcinoma 
5.1 Rucaparib (Rubraca®) maintenance treatment for recurrent 
ovarian carcinoma after response to platinum therapy  
 
Overview 
Drug Description a poly(ADP-ribose) polymerase inhibitor, 
Patient Indication 
rucaparib in patients with high-grade, recurrent, platinum-sensitive ovarian 
carcinoma 
Incidence in 
Austria 
635 newly diagnosed per year (2014), 13.8/100,000/year (European Standard 
Population, 2013) 
Ongoing Phase III - 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
10/2012: orphan designation (EU/3/12/1049) was granted for the treatment of 
ovarian cancer 
FDA 
12/2016: women with advanced ovarian cancer who have been treated with 
two or more chemotherapies and whose tumours have a specific gene 
mutation (deleterious BRCA) 
Costs - 
Phase III results  
Lancet; available online 28 October 2017 (Coleman et al.): “Rucaparib maintenance treatment for 
recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, 
placebo-controlled, phase 3 trial” 
Background 
Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian 
carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In 
this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based 
chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma. 
 
Methods 
In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 
hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a 
platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube 
carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved 
complete or partial response to their last platinum-based regimen, had a cancer antigen 125 
concentration of less than the upper limit of normal, had a performance status of 0–1, and had 
adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous 
system metastases, had received anticancer therapy 14 days or fewer before starting the study, or 
had received previous treatment with a poly (ADP-ribose) polymerase inhibitor. We randomly allocated 
patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28-day cycles using a computer-
generated sequence (block size of six, stratified by homologous recombination repair gene mutation 
status, progression-free interval after the penultimate platinum-based regimen, and best response to 
the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder 
were masked to assignments. The primary outcome was investigator-assessed progression-free 
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survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with 
BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), 
patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss 
of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks 
thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is 
complete. 
 
Findings 
Between April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib 
and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant 
carcinoma was 16.6 months (95% CI 13.4–22.9; 130 [35%] patients) in the rucaparib group versus 5.4 
months (3.4–6.7; 66 [35%] patients) in the placebo group (hazard ratio 0.23 [95% CI 0.16–0.34]; 
p<0.0001). In patients with a homologous recombination deficient carcinoma (236 [63%] versus 118 
[62%]), it was 13.6 months (10.9–16.2) versus 5.4 months (5.1–5.6; 0.32 [0.24–0.42]; p<0.0001). In 
the intention-to-treat population, it was 10.8 months (8.3–11.4) versus 5.4 months (5.3–5.5; 0.36 
[0.30–0.45]; p<0.0001). Treatment-emergent adverse events of grade 3 or higher in the safety 
population (372 [99%] patients in the rucaparib group versus 189 [100%] in the placebo group) were 
reported in 209 (56%) patients in the rucaparib group versus 28 (15%) in the placebo group, the most 
common of which were anaemia or decreased haemoglobin concentration (70 [19%] versus one [1%]) 
and increased alanine or aspartate aminotransferase concentration (39 [10%] vs none). 
 
Interpretation 
Across all primary analysis groups, rucaparib significantly improved progression-free survival in 
patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based 
chemotherapy.ARIEL3 provides further evidence that use of a poly (ADP-ribose) polymerase inhibitor 
in the maintenance treatment setting versus placebo could be considered a new standard of care for 
women with platinum-sensitive ovarian cancer following a complete or partial response to second-line 
or later platinum-based chemotherapy. 
 
